There are a few other biopharmaceutical companies that could see much more volatility lined up over the next few weeks with key FDA decisions pending. 24/7 Wall St. puts together a monthly calendar of these events and what to look for before the news hits.
Such decisions have the potential to make or break companies. There is a fair amount to a great amount of risk involved, should a study come back negative or should a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside.
In terms of Geron, the FDA granted a Fast Track designation to imetelstat for the potential treatment of adult patients with transfusion-dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes that are non-del(5q) and that are refractory or resistant to treatment with an erythropoiesis stimulating agent.
For some quick background: imetelstat is a telomerase inhibitor initially developed by Geron and exclusively licensed to Janssen Biotech, a subsidiary of Johnson & Johnson (NYSE: JNJ), on a worldwide basis. Janssen sponsored the application for Fast Track designation utilizing preliminary data from IMerge, the ongoing clinical trial being conducted by Janssen in lower risk myelodysplastic syndromes.
Through the Fast Track program, a product candidate may be eligible for priority review, if supported by the clinical data, and for the ability to submit completed sections of a New Drug Application (NDA) on a rolling basis as data become available prior to completion of the full application.
Shares of Geron were last seen trading up 7.5% at $2.21, with a consensus analyst price target of $3.75 and a 52-week trading range of $1.81 to $3.15.
Johnson & Johnson traded at $139.36 a share. The stock has a 52-week range of $109.32 to $144.35 and a consensus price target of $144.81.
Escape Credit Card Debt Quicksand With a 0% Card Today (sponsor)
Looking for a smarter way to tackle your credit card debt? A balance transfer card could be your ticket to financial freedom, finally eliminating your debt once and for all. We’ve assembled a list of the top balance transfer cards available today. Many offer a 0% introductory APR, giving YOU the chance to pay down your balance without the added cost of interest. Even better, many come with no annual fee—so you can focus on eliminating debt and keeping more money in your pocket. Click here to get started today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
